In this issue:
Surveys not reliable to assess AD prevalence
There is a significant autoimmune comorbidity in adults with AD
Efficacy and safety of JAK inhibitors for the treatment of AD
Ocular surface disorders among patients treated with dupilumab
Inaugural global best practices from the Atopic Dermatitis Quality of Care Initiative
Abrocitinib, dupilumab and upadacitinib the most effective therapies for moderate-to-severe disease
Mixed results to IL-12/23 pathway targeting with ustekinumab
Patients with AD are at increased risk of developing CVD
Dupilumab elicits rapid improvement in the extent and signs of AD in paediatric patients
Crisaborole is safe and efficacious for long-term treatment of mild-to-moderate AD
Please login below to download this issue (PDF)